ModifiedPremera Blue Cross of WashingtonPolicy 7.01.171

Remote Electrical Neuromodulation for Migraines

Customize your policy alerts

Sign up for premerabluecrossofwashington Policy 7.01.171 alerts

Get alerted when Policy 7.01.171 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage of remote electrical neuromodulation (REN), such as Nerivio, for migraine prevention and continuation of treatment. It defines medical-necessity criteria, investigational uses, coding, contraindications, and documentation expectations for providers.

Policy Summary

PayerPremera Blue Cross of Washington

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy 7.01.171

Change TypeModified

Effective DateOctober 1, 2026

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionDocument age, ICHD-3 migraine diagnosis, headache frequency, and the applicable additional qualifying circumstance for adults seeking preventive REN coverage.

SourceLink

POLICY UPDATE CHANGES

The policy added prevention of migraine to the REN policy statement based on expanded FDA-approved indications.

The policy added HCPCS code A4540.

HCPCS code K1023 was removed from the policy.

REN for prevention of migraine changed from investigational to medically necessary in adults when criteria are met, while acute migraine treatment remained investigational.

The October 2026 annual review states that the policy statement was unchanged.

The October 2026 annual review updated the literature references through June 8, 2026, while leaving the policy statement unchanged.

Beginning January 1, 2026, remote electrical neuromodulation became medically necessary for adult migraine prevention when stated criteria are met, while acute migraine treatment remained investigational.

On January 1, 2024, the policy expanded its investigational statement to include migraine prevention in addition to acute migraine treatment.

HCPCS code A4540 was added in the January 2024 policy update.

HCPCS code K1023 was removed in the January 2025 policy update.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedPremera Blue Cross of WashingtonPolicy 7.01.171

Remote Electrical Neuromodulation for Migraines

Customize your policy alerts

Sign up for premerabluecrossofwashington Policy 7.01.171 alerts

Get alerted when Policy 7.01.171 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Blue Cross of Washington

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy 7.01.171

Change TypeModified

Effective DateOctober 1, 2026

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionDocument age, ICHD-3 migraine diagnosis, headache frequency, and the applicable additional qualifying circumstance for adults seeking preventive REN coverage.

SourceLink

POLICY UPDATE CHANGES

The policy added prevention of migraine to the REN policy statement based on expanded FDA-approved indications.

The policy added HCPCS code A4540.

HCPCS code K1023 was removed from the policy.

REN for prevention of migraine changed from investigational to medically necessary in adults when criteria are met, while acute migraine treatment remained investigational.

The October 2026 annual review states that the policy statement was unchanged.

The October 2026 annual review updated the literature references through June 8, 2026, while leaving the policy statement unchanged.

On January 1, 2024, the policy expanded its investigational statement to include migraine prevention in addition to acute migraine treatment.

HCPCS code A4540 was added in the January 2024 policy update.

HCPCS code K1023 was removed in the January 2025 policy update.

AdultsAdult migraine prevention coverage

InvestigationalAcute migraine treatment status

6-24Required headache days per 28-day period

8-12 weeksMinimum benefit assessment period

A4540Nerivio HCPCS code

Medical Necessity and Coverage Criteria

Adult initial preventive therapy

Preventive REN may be considered medically necessary when all of the following are met, including at least one additional qualifying circumstance.

Adult initial preventive REN

Additional qualifying circumstance
- Preventive medication issue: Insufficient response, contraindication, or intolerance to 2 or more guideline-recommended preventive headache medications, such as anticonvulsants, antihypertensives, antidepressants, or calcitonin gene-related peptide (CGRP) inhibitors.2 or more medications
- Reproductive status: Pregnancy, breastfeeding, or planning to conceive.
- Medication-overuse risk: The individual is at risk for or has a history of medication-overuse headache.
- Drug-interaction risk: The individual is at risk for drug-drug interactions with medications for comorbid conditions.

Continuation therapy

Continued use of the REN device and/or accessories for migraine prevention is considered medically necessary when all of the following are met.

Ongoing compliance: The individual is compliant with ongoing use of the REN device and/or accessories.
Clinical benefit: Documentation of clinical benefit is provided.Assessment reasonable after a minimum of 8-12 weeks of preventive treatment
Clinical benefit may include improved pain relief or freedom, reduced headache frequency, duration, or severity, reduced functional disability or absenteeism, or reduced use of concomitant headache medications.

Pediatric preventive therapy

Preventive REN may be considered medically necessary for individuals ages 8 through 17 when all of the following are met.

Pediatric preventive REN: The individual is 8-17 years of age; headaches meet the International Classification of Headache Disorders (ICHD-3) diagnostic criteria for migraine with or without aura; and the REN device will be used for prevention in an individual with 6 to 24 headache days per 28-day period in each of the 3 months preceding use.Age 8-17; 6-24 headache days per 28-day period for each of 3 preceding months

Reduction in school absenteeism is recommended as an outcome for assessing clinical benefit in children and adolescents.

Investigational REN

The following uses are considered investigational.

Investigational uses

Acute migraine: Use of remote electrical neuromodulation for acute migraine.
Prevention outside criteria: Use of remote electrical neuromodulation for prevention of migraine outside the medical-necessity criteria stated in the policy.

Adult preventive therapy

Remote electrical neuromodulation is covered as medically necessary for adult migraine prevention when applicable criteria are met.

Adult preventive REN: Remote electrical neuromodulation for prevention of migraine is medically necessary in adults when the policy criteria are met.

The policy history states that adult preventive REN changed from investigational to medically necessary when criteria are met.

Acute treatment

Acute treatment remains investigational.

Acute migraine treatment: Remote electrical neuromodulation for acute migraine is considered investigational.

Adolescent and pediatric preventive therapy

Evidence-based population distinctions apply to adolescent and pediatric preventive use.

Adolescent or pediatric preventive use: For adolescents and children receiving REN for preventive migraine therapy, evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For adolescents, available evidence is limited and well-defined controlled studies are required. For children, preventive-use evidence is based on a retrospective real-world analysis, and well-defined controlled studies are required to confirm benefit.

Adult migraine prevention

Remote electrical neuromodulation is medically necessary for adult migraine prevention when the policy criteria are met.

Adult migraine prevention: Remote electrical neuromodulation is medically necessary for prevention of migraine in adults when the policy criteria are met.

Acute migraine treatment

Acute migraine treatment with REN is investigational.

Acute migraine treatment: Remote electrical neuromodulation for treatment of acute migraine is considered investigational.

Nerivio is contraindicated for individuals with uncontrolled epilepsy or an active implantable medical device, including a pacemaker, hearing aid implant, or any other implanted electronic device.

Nerivio has not been evaluated in individuals with congestive heart failure, severe cardiac or cerebrovascular disease, pregnancy, or those younger than 8 years.

Evidence is insufficient to determine improvement in net health outcomes for acute migraine treatment with REN and for preventive treatment in adolescents and children. Controlled studies are lacking or limited in these populations.

Preventive REN used outside the medical-necessity criteria stated in this policy is considered investigational.

REN used for the acute treatment of migraine is considered investigational.

Coding and Operational Thresholds

HCPCSHCPCS

A4540

Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm (Nerivio)

Added HCPCS CodeHCPCS

A4540

HCPCS code A4540; description not provided in this window.

Removed HCPCS CodeHCPCS

K1023

HCPCS code K1023; description not provided in this window.

HCPCS code added historicallyHCPCS

A4540

HCPCS code removed historicallyHCPCS

K1023

Pre-treatment headache frequency

Required frequency6 to 24 headache days per 28-day period

Measurement periodEach of the 3 months preceding use of the REN device

Headache-day standardA calendar day with headache regardless of severity or duration

Preventive clinical-benefit assessment

Minimum assessment period8 to 12 weeks of preventive treatment

PurposeAssessment of clinical benefit for continuation of REN use

Documentation and Coverage Risks

Documentation Required

Initial Medical-Necessity Documentation

Document that the individual is age 18 or older, meets ICHD-3 diagnostic criteria for migraine with or without aura, and has had 6 to 24 headache days per 28-day period in each of the 3 months before starting REN. Also document at least one qualifying circumstance: inadequate response, contraindication, or intolerance to two or more guideline-recommended preventive medications; pregnancy, breastfeeding, or plans to conceive; risk for or history of medication-overuse headache; or risk for drug-drug interactions with comorbid-condition medications.

Documentation Required

Continuation Documentation Required

For continued preventive REN and related accessories, document compliance with ongoing use and provide clinical-benefit documentation. A clinician attestation may describe improvements in pain relief or freedom, reduced headache frequency, duration, or severity, reduced functional disability or absenteeism, or reduced use of concomitant headache medications.

Documentation Required

Clinical Background

Migraine is a neurologic disease involving recurrent moderate to severe headaches and may include associated symptoms such as aura, photophobia, nausea, or vomiting. Episodic migraine generally occurs on 14 or fewer headache days per month, while chronic migraine involves 15 or more headache days per month for more than 3 months, with additional migraine features.

Key Definitions

Headache day

DefinitionA calendar day with headache

SeverityThe headache may be of any severity

DurationThe headache may be of any duration

Episodic migraine

Frequency threshold14 or fewer headache days per month

Headache durationUntreated or unsuccessfully treated headache lasting 4 to 72 hours

Associated featuresHeadache has at least 2 characteristic features and at least 1 associated symptom, such as nausea or vomiting, photophobia, or phonophobia

Policy Summary

PayerPremera Blue Cross of Washington

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy 7.01.171

Change TypeModified

Effective DateOctober 1, 2026

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionDocument age, ICHD-3 migraine diagnosis, headache frequency, and the applicable additional qualifying circumstance for adults seeking preventive REN coverage.

SourceLink

On This Page

Documentation basisObserved outcomes from pivotal Nerivio studies and International Headache Society study-duration recommendations

Benefit Assessment Timing

Assess and document preventive clinical benefit after a minimum of 8 to 12 weeks of treatment. Use clinically relevant outcomes such as headache-day frequency, severity or duration, functional disability, absenteeism, pain relief or freedom, and concomitant medication use.

Denial Risk

Acute Migraine Use Is Investigational

Do not submit acute migraine treatment with REN as medically necessary under this policy. Acute REN treatment is considered investigational and may be denied.

Denial Risk

Prevention Outside Criteria

Preventive REN is considered investigational when the applicable medical-necessity criteria are not met. Verify and document the adult eligibility, migraine diagnosis, headache frequency, and qualifying treatment-history or clinical-circumstance requirements before submission.

Denial Risk

Device Contraindications

Screen for contraindications before prescribing or continuing Nerivio/REN. The device is contraindicated for patients with uncontrolled epilepsy or an active implantable medical device.

Examples of active implantable medical devices include a pacemaker, hearing-aid implant, or other implanted electronic device.

Denial Risk

Investigational Use or Unmet Preventive Criteria

Acute migraine treatment with REN remains investigational. Preventive REN is medically necessary only when the applicable adult criteria are met; otherwise, preventive use is investigational and may be denied.

Denial Risk

Insufficient Pediatric Preventive Evidence

Do not rely on current evidence to establish medical necessity for preventive REN in adolescents. The evidence is insufficient to determine that preventive REN improves net health outcomes in this population.

Denial Risk

Acute Migraine Treatment Is Investigational

REN used for acute migraine treatment is considered investigational under the policy and may be denied, regardless of whether the migraine is episodic or chronic.

Chronic migraine

Frequency and durationMigraine-like or tension-type headache on 15 or more days per month for more than 3 months

Migraine-feature thresholdAt least 5 headache attacks without aura meet episodic migraine criteria 1 to 3, and/or at least 5 headache attacks with aura meet episodic migraine criteria 2 to 3

Additional ICHD-3 featureOn more than 8 days per month for more than 3 months, the headache fulfills specified migraine criteria or is believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative

Remote electrical neuromodulation

DeviceA wearable device worn on the upper arm

Stimulation targetThe device stimulates peripheral nerves

Mechanism inducedPeripheral-nerve stimulation induces conditioned pain modulation

Remote electrical neuromodulation (REN)

Treatment typeA wearable peripheral-nerve stimulation treatment

Typical placementThe device is typically worn on the upper arm

Device controlThe device is controlled through a smartphone or tablet application using Bluetooth communication

Conditioned pain modulation (CPM)

Proposed mechanismPainful stimulation in one body area reduces perceived pain intensity in another area

Application to migraineConditioned pain in the arm is believed to reduce the perceived intensity of migraine pain

Role in RENCPM is induced by stimulation of peripheral nerves with the upper-arm device

Nerivio

FDA-cleared age rangePatients 8 years of age and older

Acute indicationAcute treatment of migraine with or without aura

Preventive indicationPreventive treatment of migraine with or without aura